Matrix Labs has filed a total of 64 DMFs including 4 DMFs in the first quarter of current year with the US authorities. The company has also filed 4 patents during the year, taking the total tally to 56.
"In 2006-07, the company is focusing on consolidation and initiated various measures for capturing synergies that would arise from the strategic initiatives completed in the previous year", said Rajiv Malik, CEO, Matrix Laboratories.
The company had a successful audit from the US FDA in one of its API manufacturing facilities (Unit VIII) located at Vishakapatnam, during the first quarter.
The company witnessed robust growth in the ARV segment on account of good demand from all the existing major customers. The company is in the process of working with Aspen for filing for regulatory approvals for Atazanavir, a product in-licensed from BMS, during the current year.
Matrix-India successfully finalized a supply agreement with a US generic company for development, manufacture and supply of a range of finished dosage products, during the quarter. This portfolio consists of a mix of off-patent and soon to go off-patent products. The company has filed its second ANDA with the US FDA and has taken exhibit batches for a number of products.
The multiple projects under CRAM business initiated with leading pharma companies are responsible for good growth of the company and this trend is expected to add further growth to this segment during the remaining period of the current year.